News
APR 2, 2024
DD01 Fast Track Designation and Expanded Access Policy
Neuraly is conducting clinical trials of DD01 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in North America on behalf of D&D Pharmatech Inc. In March 2024, DD01 was granted fast track designation by the U.S. Food and Drug Administration (FDA).You can find additional information on DD01 clinical trials by accessing https://clinicaltrials.gov. For more information on D&D Pharmatech’s DD01 program and its expanded access policy please visit http://www.ddpharmatech.com/.
MAR 27, 2023
Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson’s Disease
Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced topline results from the Phase 2 trial with NLY01 in patients with early, untreated Parkinson’s disease (PD).
APR 19, 2022
Neuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with Parkinson’s Disease
Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinson’s disease (PD).
JAN 28, 2022
How the Prism Parkinson’s Research Study Might Change the Way We Treat Parkinson’s
Three times in history, the stars aligned to create an environment in which a Parkinson’s breakthrough therapy was possible.
The first was in 1960, when scientists first realized that dopamine was linked to Parkinson’s — a realization that helped researchers discover how levodopa could treat symptoms.
OCT 19, 2021
D&D Pharmatech Raises $51M in Series C Financing to Advance Potential Disease-Modifying Treatments for Neurodegenerative, Fibrotic, and Metabolic Diseases
D&D Pharmatech, a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, and parent company of U.S.-based Neuraly Inc., Precision Molecular, Inc., Theraly Fibrosis Inc., P4Microbiome…
Full Article
OCT 18, 2021
Dr. Ted Dawson elected to the National Academy of Medicine
Ten Johns Hopkins University faculty members have been elected to the National Academy of Medicine, an independent organization of leading professionals from diverse fields, including health, medicine, and the natural, social, and behavioral sciences.
JUN 15, 2021
D&D Pharmatech Appoints Yoo-Seok Hong as Chief Executive Officer
GSK veteran brings decades of commercial expertise as D&D advances pipeline of clinical candidates for neurodegenerative diseases and fibrosis.
APR 28, 2021
Neuraly Announces Publication in Acta Neuropathologica Communications of Preclinical Data Detailing the Neuroprotective Effect of NLY01 in Models of Alzheimer’s Disease
NLY01 selectively blocks β-amyloid-induced activation of microglia through upregulated GLP-1R. Neuronal viability was preserved, resulting in improved spatial learning and memory
APR 27, 2021
Renowned scientist Dr. Ted Dawson to receive Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research
Van Andel Institute has chosen internationally recognized Parkinson’s disease expert Ted Dawson, M.D., Ph.D, to receive its 2021 Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research.
MAR 5, 2021
Qi Cui, AGS 2021: The GLP-1R Agonist NLY01 Reduces Neuroinflammation and Protects against RGC Loss in a Preclinical Glaucoma Model
We were delighted to catch up with Dr Qi Cui (Scheie Eye Institute, University of Pennsylvania, PA, USA), who told us about her research on the GLP-1R agonist NLY01 and the next steps for clinical development.
NOV 10, 2020
Neuraly Announces Research Agreement with the University of Pennsylvania to Explore Use of NLY01 for Glaucoma
Study recently published by Penn team in Cell Reports provides evidence that NLY01 has the potential for clinical use in the treatment of glaucoma and potentially other retinal diseases
NOV 2, 2020
Receiving FDA Clearance of IND Application to Initiate Phase 2B Trial of NLY01 for Patients with AD
Neuraly announced it has received clearance of an investigational new drug application (IND) to initiate a Phase 2B trial of NLY01 in patients with Alzheimer’s disease.
MAR 3, 2020
Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease
Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the dosing of the first patient in its Phase 2 clinical trial of NLY01 for Parkinson’s disease.
NOV 5, 2019
The Neuraly Trial
This week a new clinical trial was registered which caught our attention here at the SoPD HQ. It is being sponsored by a small biotech called Neuraly and involves a drug called NLY01.
OCT 4, 2019
Monster investment puts Baltimore on biotech startup map
With neuroinflammation, fibrosis, genomics and apoptosis research to the fore, Johns Hopkins is ramping up its output of startups with a little help from Korea.
AUG 14, 2019
D&D Pharmatech raises $137.1M in series B financing to advance potential disease-modifying treatments
The financing was led by U.S.-based Octave Life Sciences and included major Korean venture funds Smilegate Investment as co-lead, along with InterVest, Magna Investment and LB Investment, all Series A investors.
JUL 18, 2018
Startup Neuraly raises $36M to bring potential disease-modifying treatments to patients with Parkinson’s disease
Today, Neuraly announced its launch to pioneer the development of disease-modifying agents for neurodegenerative disorders.
JUN 28, 2018
Diabetes drug affects neurodegeneration, PD via immunity
Scientists at the Johns Hopkins Medical School have demonstrated that the experimental glucagon-like peptide 1 (GLP-1) receptor agonist NLY-01 (Neuraly Inc.) was protective against Parkinson's disease (PD) in two separate mouse models.
Jun 13, 2018
Does taming killer astrocytes spare neurons in Parkinson’s disease?
Activated microglia contribute to neurodegenerative diseases, and recent work suggests they do that, at least in part, by riling up normally protective astrocytes to attack and kill neurons.
OCT 30, 2018
Neuraly and South Korea-based 1st Biotherapeutics agreed to co-develop brain penetrant c-Abl inhibitors for Parkinson’s disease
Neuraly Inc., a startup from Johns Hopkins School of Medicine and South Korea-based 1st Biotherapeutics Inc. agreed to co-develop brain penetrant c-Abl inhibitors for Parkinson's disease with aims to file an investigational new drug (IND) application with the FDA next year.